Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in
microalgae-based, high-value nutrition and health products, today
announced financial results for the first quarter of fiscal year 2014,
ended June 30, 2013.
First Quarter 2014
For the first quarter of fiscal 2014 compared to the first quarter of
fiscal 2013, net sales were $6,909,000 compared to $6,506,000, an
increase of 6%. Gross profit was $2,852,000, with gross profit margin of
41.3%, compared to gross profit of $2,574,000 and gross profit margin of
39.6%. Net income was $30,000 or $0.01 per diluted share, compared to
net income of $493,000 or $0.08 per diluted share.
After having recognized a $2,021,000 tax benefit during the quarter
ended March 31, 2013 from the release of a valuation allowance against
deferred tax assets, the Company now recognizes a provision for income
taxes. As a result, the Company’s effective tax rate increased during
the quarter ended June 30, 2013. Pretax income for the first quarter was
$136,000 compared to $503,000 for the first quarter of fiscal 2013.
Regarding the first quarter of fiscal 2014 results (changes shown versus
the first quarter of fiscal 2013), Brent Bailey, President and CEO,
stated, “First quarter results keep us on track to achieve our full year
objectives.
“Total company net sales growth in the first quarter was a modest +6%.
However, our consumer products business (Nutrex) grew +44% and accounted
for 55% of net sales in the quarter:
|
|
•
|
|
Nutrex Mainland:
|
|
|
+64%
|
|
|
•
|
|
Nutrex Hawaii:
|
|
|
+34%
|
|
|
•
|
|
Nutrex Direct:
|
|
|
+45%
|
|
|
•
|
|
Nutrex International:
|
|
|
+22%
|
|
|
|
|
|
|
|
|
“Retail sales growth of our Astaxanthin products in the U.S. natural
products channel was +84% with market share of 52.8% (+21.8 pts.). Our
Spirulina retail dollar growth for the quarter was +39% with a market
share of 48.8% (+7.3 pts.). Continuing the focus on building our
consumer packaged business, we recently began a test of our Hawaii
marketing plan in a West Coast market. Initial results have been very
encouraging, with growth more than 40% greater than the remainder of the
country after the first two months.
“Operating income for the first quarter met our expectations and was
impacted by the cost of the West Coast test market, as well as the costs
associated with the people and infrastructure investments that were
begun in fiscal 2013 and which are driving the strong topline growth we
are seeing in our consumer business. Additionally, legal fees increased
compared to the first quarter of last year.”
Trailing 12 Months
For the trailing 12 months ended June 30, 2013 compared to the trailing
12 months ended June 30, 2012, net sales were $27,984,000 compared to
$25,187,000, an increase of 11.1%. Gross profit was $11,236,000, with
gross profit margin of 40.2%, compared to gross profit of $10,244,000
and gross profit margin of 40.7%. Net income was $3,746,000 or $0.67 per
diluted share, compared to net income of $3,639,000 or $0.65 per diluted
share.
About Cyanotech — Cyanotech Corporation, a world leader in
microalgae technology, produces BioAstin® Natural Astaxanthin and
Hawaiian Spirulina Pacifica®—all natural, functional nutrients
that leverage our experience and reputation for quality, building
nutritional brands which promote health and well being. Cyanotech's
Spirulina products offer complete nutrition, and augment energy and
immune response. They are FDA-reviewed and accepted as Generally
Recognized as Safe (GRAS) for use in food products. BioAstin's superior
antioxidant activity and ability to support and maintain a natural
anti-inflammatory response enhance skin, muscle and joint health. All
Cyanotech products are produced from microalgae grown at our 90-acre
facility in Kona, Hawaii using patented and proprietary technology.
Cyanotech distributes to nutritional supplement, nutraceutical and
cosmeceutical manufacturers and marketers in more than 40 countries
worldwide. Cyanotech was the first microalgae company in the
world to obtain quality management standards ISO 9001:2000 certification
and is GMP-certified by the Natural Products Association™. Visit www.cyanotech.com
for more information.
“Safe Harbor” Statement under the U.S. Private Securities Litigation
Reform Act of 1995 — Besides statements of present fact and
historical fact, this press release may contain forward-looking
statements. Forward-looking statements relate to the future and are
subject to inherent uncertainties, risks and changes in circumstances
that are difficult to predict. Our actual results may differ materially
from those contemplated by forward-looking statements. We caution
against relying on forward-looking statements. Important factors that
could change actual, future results include: changes in sales levels to
our largest customers, weather patterns in Hawaii, production problems,
risks associated with new products, foreign exchange fluctuations, and
availability of financing, as well as national and global political,
economic, business, competitive, market and regulatory conditions. Other
factors are more fully detailed in the Company’s annual Form 10-K
filings with the Securities and Exchange Commission.
(Financial Tables Follow: The following tables do not contain
footnotes or other information contained in the Company’s Form 10-Q for
the period ended June 30, 2013. As such the following Financial Tables
are provided only as a guide and other factors are more fully detailed
in the Company’s annual Form 10-K filings with the Securities and
Exchange Commission.)
|
CYANOTECH CORPORATION
|
CONDENSED CONSOLIDATED BALANCE SHEETS
|
(Dollars in thousands except par value and number of shares)
|
(Unaudited)
|
|
|
|
|
|
|
June 30, 2013
|
|
|
|
|
March 31, 2013
|
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
|
|
$
|
3,104
|
|
|
|
|
|
$
|
4,364
|
|
Accounts receivable, net of allowance for doubtful accounts of $6 at
June 30, 2013 and $6 at March 31, 2013
|
|
|
|
|
3,896
|
|
|
|
|
|
3,766
|
|
Inventories, net
|
|
|
|
|
4,213
|
|
|
|
|
|
3,688
|
|
Deferred tax assets
|
|
|
|
|
110
|
|
|
|
|
|
110
|
|
Prepaid expenses and other current assets
|
|
|
|
|
651
|
|
|
|
|
|
263
|
|
Total current assets
|
|
|
|
|
11,974
|
|
|
|
|
|
12,191
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equipment and leasehold improvements, net
|
|
|
|
|
10,198
|
|
|
|
|
|
8,835
|
|
Restricted cash
|
|
|
|
|
2,717
|
|
|
|
|
|
3,360
|
|
Deferred tax assets
|
|
|
|
|
3,323
|
|
|
|
|
|
3,429
|
|
Other assets
|
|
|
|
|
811
|
|
|
|
|
|
772
|
|
Total assets
|
|
|
|
|
$
|
29,023
|
|
|
|
|
|
$
|
28,587
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
Current maturities of long-term debt
|
|
|
|
|
$
|
156
|
|
|
|
|
|
$
|
128
|
|
Customer deposits
|
|
|
|
|
29
|
|
|
|
|
|
33
|
|
Accounts payable
|
|
|
|
|
2,209
|
|
|
|
|
|
1,852
|
|
Accrued expenses
|
|
|
|
|
751
|
|
|
|
|
|
872
|
|
Total current liabilities
|
|
|
|
|
3,145
|
|
|
|
|
|
2,885
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term debt, excluding current maturities
|
|
|
|
|
5,418
|
|
|
|
|
|
5,454
|
|
Deferred rent
|
|
|
|
|
21
|
|
|
|
|
|
21
|
|
Total liabilities
|
|
|
|
|
8,584
|
|
|
|
|
|
8,360
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ equity:
|
|
|
|
|
|
|
|
|
|
|
|
Common stock of $0.02 par value, shares authorized 50,000,000;
5,465,788 shares issued and outstanding at June 30, 2013 and
5,463,938 at March 31, 2013
|
|
|
|
|
109
|
|
|
|
|
|
109
|
|
Additional paid-in capital
|
|
|
|
|
29,259
|
|
|
|
|
|
29,077
|
|
Accumulated deficit
|
|
|
|
|
(8,929
|
)
|
|
|
|
|
(8,959
|
)
|
Total stockholders’ equity
|
|
|
|
|
20,439
|
|
|
|
|
|
20,227
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders’ equity
|
|
|
|
|
$
|
29,023
|
|
|
|
|
|
$
|
28,587
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CYANOTECH CORPORATION
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
(Dollars in thousands, except per share amounts)
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30,
|
|
|
|
|
|
2013
|
|
|
|
|
2012
|
|
|
|
|
|
|
|
|
|
|
|
NET SALES
|
|
|
|
|
$
|
6,909
|
|
|
|
|
$
|
6,506
|
COST OF SALES
|
|
|
|
|
4,057
|
|
|
|
|
3,932
|
Gross Profit
|
|
|
|
|
2,852
|
|
|
|
|
2,574
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING EXPENSES:
|
|
|
|
|
|
|
|
|
|
|
General and administrative
|
|
|
|
|
1,556
|
|
|
|
|
1,148
|
Sales and marketing
|
|
|
|
|
1,004
|
|
|
|
|
838
|
Research and development
|
|
|
|
|
115
|
|
|
|
|
51
|
Loss on disposal of equipment and leasehold improvements
|
|
|
|
|
5
|
|
|
|
|
22
|
Total operating expenses
|
|
|
|
|
2,680
|
|
|
|
|
2,059
|
|
|
|
|
|
|
|
|
|
|
|
Income from operations
|
|
|
|
|
172
|
|
|
|
|
515
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense, net
|
|
|
|
|
36
|
|
|
|
|
12
|
|
|
|
|
|
|
|
|
|
|
|
Income before provision for income taxes
|
|
|
|
|
136
|
|
|
|
|
503
|
|
|
|
|
|
|
|
|
|
|
|
PROVISION FOR INCOME TAXES
|
|
|
|
|
106
|
|
|
|
|
10
|
|
|
|
|
|
|
|
|
|
|
|
NET INCOME
|
|
|
|
|
$
|
30
|
|
|
|
|
$
|
493
|
|
|
|
|
|
|
|
|
|
|
|
NET INCOME PER SHARE:
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
|
|
$
|
0.01
|
|
|
|
|
$
|
0.09
|
Diluted
|
|
|
|
|
$
|
0.01
|
|
|
|
|
$
|
0.08
|
|
|
|
|
|
|
|
|
|
|
|
SHARES USED IN CALCULATION OF NET INCOME PER SHARE:
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
|
|
5,464
|
|
|
|
|
5,441
|
Diluted
|
|
|
|
|
5,615
|
|
|
|
|
5,873
|
Copyright Business Wire 2013